Abstract:We herein report the synthesis, characterization, and anticancer activity of a series of iridium(III) and ruthenium(II) half-sandwich complexes of the type 6 [(Cp-x/arene)M((PO)-O-boolean AND)Cl]PF6 (M = Ir, Cp-x = pentamethylcyclopentadienyl (Cp*) or its phenyl (Cp-xPh = C5Me4C6H5) or biphenyl (Cp-xbiPh = C5Me4C6H4C6H5) derivatives; M = Ru, arene = p-cymene (p-cym); (PO)-O-boolean AND = phosphine phosphonic amide ligand (PPOA)). The X-ray crystal structures of all complexes, in which the ligand can form six-membered rings with the metal center, have been determined. All of the complexes show remarkable anticancer activities toward HeLa and A549 cancer cells, activities which are higher than that of the clinical anticancer drug cisplatin. The incorporation of phenyl substituents on the Cp* ring for iridium(III) complexes results in little variation in their anticancer activities. These results can be attributed to the combinatorial action of the metal and PPOA ligand. Hydrolysis and DNA cleavage are not the major mechanisms of action. These complexes show potent catalytic activity in the transfer hydrogenation of NADH to NAD(+). Additionally, complexes [(eta(5)-C5Me5)Ir((PO)-O-boolean AND)Cl]PF6 (1) and [(eta(6)-p-cym)Ru((PO)-O-boolean AND)Cl]PF6 (4) arrest cell cycles at S and G(2)/M phase and S phase, respectively. Complexes 1 and 4 both can induce apoptosis of HeLa cancer cells. Reactive oxygen species (ROS) and mitochondrial membrane potential tests were also performed to explore the mechanism of action. When the concentration of the complexes is increased, the amount of reactive oxygen species (ROS) increases dramatically and the mitochondrial membrane potential decreases significantly in HeLa cancer cells. Overall, cell stress including cell cycle perturbation, apoptosis induction, increase in ROS level, and loss of mitochondrial membrane potential contributes to the anticancer potency of these complexes. Interestingly, the use of confocal microscopy provides insights into the microscopic mechanism in which the typical and most active complex 1 can damage lysosomes. This type of complex represents a potent platform for development of metal anticancer drugs.

Triphenylamine/carbazole-modified ruthenium(ii) Schiff base compounds: synthesis, biological activity and organelle targeting

Half‐sandwich Ruthenium (II) Complexes with Triphenylamine Modified Dipyridine Skeleton and Application in Biology/luminescence Imaging

Dual Functional Half-Sandwich Ru(II) Complexes: Lysosome-Targeting Probes and Anticancer Agents

Ruthenium(II) Complexes with 2-Phenylimidazo[4,5-f][1,10]phenanthroline Derivatives that Strongly Combat Cisplatin-Resistant Tumor Cells

Synthesis, characterization, and anticancer activity of ruthenium(II)-β-carboline complex.

Triphenylphosphine-Modified Iridium III , Rhodium III , and Ruthenium II Complexes to Achieve Enhanced Anticancer Selectivity by Targeting Mitochondria

Organometallic ruthenium and iridium phosphorus complexes: Synthesis, cellular imaging, organelle targeting and anticancer applications: Organometallic Complexes Synthesis and Applications

Fortuitous synthesis of unsaturated half-sandwich Ruthenium(II) complexes via solvent-involved rearrangement and their biological evaluation

Synthesis, characterization, and antitumor activity of mononuclear and dinuclear ruthenium complexes

Synthesis, Crystal and Electronic Structure, Anticancer Activity of Ruthenium(Ii) Arene Complexes with Thiosemicarbazones

Lysosome-targeted Iridium(iii) Compounds with Pyridine-Triphenylamine Schiff Base Ligands: Syntheses, Antitumor Applications and Mechanisms

Synthesis, Characterization, Cellular Uptake and Apoptosis-Inducing Properties of Two Highly Cytotoxic Cyclometalated Ruthenium(ii) Β-Carboline Complexes.

16-Electron Half-Sandwich Rhodium(III), Iridium(III), and Ruthenium(II) Complexes As Lysosome-Targeted Anticancer Agents

Mitochondria-targeted half-sandwich rutheniumII diimine complexes: anticancer and antimetastasis via ROS-mediated signalling

Serendipitous Synthesis of Five-Coordinated Half-Sandwich Aminoimine Iridium(III) and Ruthenium(II) Complexes and Their Application As Potent Anticancer Agents

Synthesis, Cytotoxicity and Anti‐metastatic Properties of New Pyridyl–thiazole Arene Ruthenium(ii) Complexes

Cytotoxicity in vitro, cellular uptake, localization and apoptotic mechanism studies induced by ruthenium(II) complex

Insights into the antineoplastic activity and mechanisms of action of coumarin-coordinated 8-hydroxyquinoline ruthenium(II/III) compounds

Labile ruthenium(ii) complexes with extended phenyl-substituted terpyridyl ligands: synthesis, aquation and anticancer evaluation.

Synthesis, structures, antiproliferative activity of a series of ruthenium(II) arene derivatives of thiosemicarbazones ligands

Potent Half-Sandwich Iridium(III) and Ruthenium(II) Anticancer Complexes Containing a P^O-Chelated Ligand